What it is
CJC-1295 without DAC is a short-acting GHRH analog studied for discrete GH pulses.
Evidence boundary
Investigational / limited human evidence.
Trial evidence
- PMID 42395176 — The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
- PMID 42160466 — Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
- PMID 41476424 — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 100 mcg | 2 U (0.02 mL) | 1–3× daily | 700 mcg/week |
| Weeks 3–4 | 150 mcg | 3 U (0.03 mL) | 1–3× daily | 1.05 mg/week |
| Weeks 5–6 | 200 mcg | 4 U (0.04 mL) | 1–3× daily | 1.4 mg/week |
| Weeks 7–12 (target) | 250 mcg | 5 U (0.05 mL) | 1–3× daily | 1.75 mg/week |
Weeks 1–2 (titration)
- Dose
- 100 mcg
- Draw / measure
- 2 U (0.02 mL)
- Frequency
- 1–3× daily
- Weekly total
- 700 mcg/week
Weeks 3–4
- Dose
- 150 mcg
- Draw / measure
- 3 U (0.03 mL)
- Frequency
- 1–3× daily
- Weekly total
- 1.05 mg/week
Weeks 5–6
- Dose
- 200 mcg
- Draw / measure
- 4 U (0.04 mL)
- Frequency
- 1–3× daily
- Weekly total
- 1.4 mg/week
Weeks 7–12 (target)
- Dose
- 250 mcg
- Draw / measure
- 5 U (0.05 mL)
- Frequency
- 1–3× daily
- Weekly total
- 1.75 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Standard (100 mcg, 2–3× daily): Multiple GH pulses across the day. Common research protocol.
-
Timing: Avoid eating for 30+ minutes after each dose — meals blunt GH release. Pre-bed dosing aligns with natural overnight pulse during slow-wave sleep.
-
GH pulse pattern
-
Sleep and recovery
-
Hunger changes
-
Water retention
-
Injection-site reactions
Practical rules
- Pre-bed timing is common in the collected notes.
- Avoid eating right after dosing.
- Keep training and sleep steady.
- Rotate sites.
Related protocols
CJC-1295 (DAC) Peptide Protocol & DosingIpamorelin Peptide Protocol & DosingGHRP-2 Peptide Protocol & DosingSermorelin Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for CJC-1295 (No DAC) Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes